TABLE 1.

Subject and Radiopharmaceutical Summary

Subject and Pathology						SN Status+ (#)	Radiopharmaceutical
Subject	Age (yrs)	Diagnosis	Size (cm)	Stage	Site		RP	Dose (mCi)
1	59	Inv ductal & Lob	0.8	T1bN0MX	RUOQ	0/2	fTcSC	0.55
2	60	Inv spindle-cell	2.1	T2N0M0	LUOQ	0/2	Lymphoseek	0.48
3	55	Inv ductal	1.0	T1N0MX	RUOQ	0/4	Lymphoseek	0.46
4	65	Multifocal DCIS	1.1	TisN0MX	LUOQ	0/7	Lymphoseek	0.56
5	57	Inv mixed duc & lob	1.5	T1cN1M0	LUOQ	1/2/12	fTcSC	0.49
6	64	Inv mixed duc & lob	2.0	T1cN0MX	LLIQ	0/5	fTcSC	0.47
7	46	Inv ductal	1.2	T1cN0 (I+)MX	RUIQ	1†/3	Lymphoseek	0.48
8	51	Inv mixed duc & lob	2.0	T1cN2aMX	RUOQ	4/8/35	Lymphoseek	0.50
9	83	Inv duc & DCIS	1.8	T1bN0MX	LUOQ	0/10	fTcSC	0.43
10	55	Inv duc & DCIS	1.1	T1cN0MX	RUIQ	0/4	fTcSC	0.52

Inv, invasive; DCIS, ductal carcinoma in situ; fTcSC, filtered [^99mTc]sulfur colloid;

⁺positive/SLN/axillary dissection,

^†Immunopositive